Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Caldwell Strengthens Human Resources Practice with Addition of Ali Palmer as Partner17.9.2026 14:50:00 CEST | Press release
TORONTO, ON AND LONDON, UK / ACCESS Newswire / September 17, 2026 / Retained executive search firm Caldwell (TSX:CWL)(OTCQX:CWLPF) today announced the addition of Ali Palmer as a Partner in the firm's Human Resources Practice. Based in London, Palmer advises boards, chief executive officers and chief people officers on the recruitment of senior human resources leaders, helping organizations build leadership teams that enable growth, transformation and long-term performance. Ali Palmer, Partner in Caldwell's Human Resources Practice. With more than 20 years of executive search and leadership advisory experience, Palmer partners with listed companies, private equity-backed businesses and privately held organizations across a broad range of sectors, with particular expertise in consumer, retail, industrial, financial services, pharmaceutical and technology. She leads executive search assignments across the full human resources function, from chief people officers and chief human resources
Freedom Holding Corp. Backs the FIDE World Championship Match 2026 as General Partner17.9.2026 14:00:00 CEST | Press release
NEW YORK CITY, NY / ACCESS Newswire / September 17, 2026 / Freedom Holding Corp. (NASDAQ:FRHC) is the General Partner of the Salesforce FIDE World Championship Match 2026, the International Chess Federation (FIDE) and Freedom announced today. General Partner is the highest partnership tier of the World Championship. The Match runs from 22 November to 12 December. The Opening Ceremony takes place on 22 November at the Palais des Nations in Geneva. World Champion Gukesh Dommaraju of India defends his title against Javokhir Sindarov of Uzbekistan over 14 classical games. Both players will be twenty at the start of the Match, the youngest title contest since the series began in 1886. Freedom has been a strategic partner of FIDE since 2023. The group is a regular sponsor of the FIDE World Rapid and Blitz Championships and was the title sponsor of the 2024 FIDE World Corporate Chess Championship in New York. Under a 2026 cooperation agreement, Freedom also funds FIDE tournaments, training ce
Bayer to Present How it Rebuilt Global Planning with OMP at Gartner Supply Chain Planning Summit 202617.9.2026 13:52:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / September 17, 2026 / OMP, a leading provider of supply chain planning solutions, invites attendees of the Gartner Supply Chain Planning Summit 2026 in London to its joint session with multinational Bayer. Representatives of the Pharmaceutical division and the global IT department will show what it took to rebuild global planning around faster, higher-quality decisions, how Unison Planning™ supports that at scale, and where AI fits in. Rebuilding planning at Bayer's scale Bayer treated its move to Unison Planning™ as more than a system replacement, rebuilding processes, master data, and ways of working across its global manufacturing and affiliate network. During their Gartner session, Mirja Meyer, Principal Product Manager and Program Lead IT at Bayer, and Karsten Hahm, Program Lead OMP Implementation at Bayer Pharmaceuticals, will cover:What adoption actually tookWhat changed in decision speed and qualityWhere AI fits on the roadmap ahead Sign up for
U.S. Polo Assn. Celebrates New Partnership with the Historic Greenwich Polo Club at the 2026 East Coast Open Presented by Audi17.9.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / September 17, 2026 / U.S. Polo Assn.®, the official sports brand of the United States Polo Association (USPA), celebrated the conclusion of the 2026 East Coast Open Presented by Audi, held August 30 through September 13 at the renowned Greenwich Polo Club in Greenwich, Connecticut, a celebrated polo destination just outside New York City. As the only high-goal tournament on the East Coast during the summer season, the historic championship once again brought together elite international competition for the sport of polo. 2026 East Coast Open Presented by Audi Winners, IGEA, celebrating with tournament trophy. Photo Credit: Greenwich Polo Club The 2026 season also marked a significant milestone as U.S. Polo Assn. served as the Official Apparel Brand Sponsor of Greenwich Polo Club for the first time. The new partnership connected one of the world's most recognized sports brands with one of polo's most iconic venues, further strengthening the brand'
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops16.9.2026 19:30:00 CEST | Press release
Short Takeoff and Landing Aircraft Validates Austere Field Capabilities SAN DIEGO, CA / ACCESS Newswire / September 16, 2026 / General Atomics Aeronautical Systems (GA-ASI) and Hanwha Aerospace have completed the first-ever flight operations from a simulated battlefield by a medium altitude, long endurance uncrewed aircraft. The partners proved that the Mojave Short Takeoff and Landing aircraft, or Mojave STOL, could land at a tank and artillery live-fire range during simulated combat conditions and then take off again to continue the mission. "This demonstration showcased Mojave's ability to perform tactical missions that are representative of real battlefield requirements and challenges," said GA-ASI CEO Linden Blue. "Whether the user needs contested and austere battlefield operations, ISR, weapons delivery, Air-Launched Effects deployment, troop resupply, counter-UAS, or missions requiring short and unimproved roads for takeoff, our aircraft answer the bell." "This demonstration mar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom